The potential of insulin to mitigate against this hyperglycemic effect on myocardial ischemia/reperfusion injury is currently unclear, although clinical trials of glucose-insulin-potassium (GIK) therapy for acute myocardial infarction are certainly relevant. The gene discussed is INS; the disease is myocardial ischemia.